BNCC *Acholeplasma laidlawii* Quality Control Product: An Essential Tool for Mycoplasma Testing Quality Control

*Acholeplasma laidlawii* is a frequent source of contamination in cell culture and biopharmaceutical processes. Lacking a cell wall, this bacterium easily penetrates sterilizing-grade filters, damages cells, and interferes with experimental results; it is also a designated quality control strain for mycoplasma testing in pharmacopoeias worldwide. The BNCC *Acholeplasma laidlawii* quality control product is designed to support quality control across the entire mycoplasma testing workflow.

Product Catalog

Key Product Advantages

Reliable strain origin and excellent batch-to-batch stability ensure reproducible experimental results; helps identify false negatives and false positives, thereby reducing experimental and production risks; meets pharmacopoeia testing and validation requirements, catering to the quality control needs of biopharmaceutical laboratories.

Key Application Areas

· Quality control for biological product release: Serves as a positive reference for pharmacopoeia mycoplasma test system suitability, used in compliant release testing for monoclonal antibodies, vaccines, and cell therapy products.

· Cell culture quality control screening: Acts as a routine positive control for mycoplasma PCR in cell laboratories, helping to rule out false negatives and prevent the spread of contamination.

· IVD kit R&D and QC: Used for sensitivity and precision validation as well as final product inspection of mycoplasma nucleic acid detection kits.

· Laboratory proficiency testing: Used as blind samples for proficiency testing and inter-laboratory comparisons to unify testing benchmarks and standardize results.

With accurate quantification and rigorous quality control, the BNCC *Acholeplasma laidlawii* quality control product safeguards experimental data integrity and product quality safety.